Intarcia is developing a subcutaneously implantable pump device for Type 2 diabetes which provides a supply of drug for up to one year. Here is a press release of their recent Ex-US deal with Servier. The deal gives them $171M upfront and additional bio bucks bringing the total potential deal to over $1B. The product is in Phase III which helped the valuation but illustrates the current opportunity in this space.

http://www.intarcia.com/media/press-...rtnership.html

ttfn
nopoo
Rick M.
aheadoftheherd